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Context: Elevated levels of retinol binding protein-4 (RBP4) are positively correlated with insulin
resistance, obesity, diabetes mellitus, and cardiovascular disease (CVD). Subclinical hypothyroidism
(SCH) has also been associated with CVD; however, the factors linking SCH to CVD are not clear.
Objective: The objective of the study was to evaluate risk factors for CVD in elderly patients
grouped according to thyroid function.
Design: 217 subjects (65 yr old) were randomly selected from a population and allocated to a
euthyroid group (n  177) and an SCH group (n  40) on the basis of plasma concentrations of TSH
and free T4. We included subjects with normal glucose tolerance by a 75-g oral glucose tolerance
test and subjects with impaired fasting glucose. We measured anthropometric parameters, levels
of fasting glucose and insulin, hemoglobin A1c, adiponectin, RBP4, lipid profiles, total body fat
content, and the area of sc and visceral fat.
Results: The SCH group had higher RBP4 levels than the euthyroid group, irrespective of body mass
index and fat content. Subcutaneous and visceral fat areas and total body fat percentage did not
differ between groups and were not correlated with RBP4 level. Other CVD risk factors did not
differ between groups. RBP4 level was positively correlated with TSH level (r  0.241, P  0.001)
after adjustment for age, sex, and body mass index.
Conclusions: Plasma RBP4 levels were associated with SCH independent of obesity in elderly sub-
jects with normal glucose tolerance, indicating that RBP4 level could be used as an index of CVD
risk in SCH. (J Clin Endocrinol Metab 93: 2313–2318, 2008)
Retinol binding protein-4 (RBP4) was recently identified as anovel adipocytokine that is expressed and secreted by ad-
ipose tissue and the liver (1). RBP4 expression is elevated in the
adipose tissue of adipocyte-specific GLUT4 knockout mice and
is substantially elevated in obese and insulin-resistant humans.
Insulin resistance in mice can be induced by RBP4 overexpres-
sion or by injection of recombinant RBP4; RBP4 knockout mice
are insulin sensitive (1–3). Although several clinical studies have
shown positive correlations between RBP4 level and insulin re-
sistance (4–10), not all reports are consistent (11). Serum RBP4
level is also correlated with visceral adiposity (12), body mass
index (BMI) (3), liver fat content (13), incipient nephropathy in
type 2 diabetes (14), and dyslipidemia (15), which suggests that
an elevated RBP4 level may be associated with the cardiovascular
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Cardiovascular disease (CVD) is a major cause of morbidity
and mortality, and it is well known that thyroid dysfunction,
especially hypothyroidism, is associated with increased cardio-
vascular risk (16). The prevalence of subclinical hypothyroidism
(SCH) is high among the elderly (17), and cardiometabolic risk
factors are particularly important in older individuals with ab-
normal thyroid function (18). It has been suggested by some that
SCH is an independent risk factor for CVD (19–22), but other
reports are conflicting (23–26).
There are no reports on the association of RBP4, an emerging
surrogate marker for cardiometabolic risk, with SCH. There-
fore, we compared several metabolic parameters, including
plasma RBP4 concentrations, in euthyroid and subclinically hy-
pothyroid elderly individuals who did not have diabetes or im-
paired glucose tolerance (IGT) to elucidate the effect of abnormal
glucose metabolism on adipocytokines and CVD risk factors.
Subjects and Methods
Subjects
Between September 2005 and September 2006, 992 elderly individ-
uals 65 yr old or older and living in Seongnam City, South Korea, were
randomly selected. They were then contacted by letter and telephone and
asked to participate in the Korean Longitudinal Study on Health and
Aging. The study was designed as a population-based prospective cohort
study of Korean elderly people. After exclusion of 420 respondents who
had been treated as diabetes or dyslipidemia, 572 subjects were enrolled
in this study. Respondents were classified into five groups on the basis of
the results of a 75-g oral glucose tolerance test (OGTT) and the American
Diabetes Association criteria (27). The groups were: normal glucose
tolerance (NGT) (n  163), impaired fasting glucose (IFG) only (n  118,
fasting glucose  100–125 mg/dl), IGT only (n  90, OGTT 2-h glu-
cose  140–199 mg/dl), both IFG and IGT (n  95), and recently di-
agnosed with diabetes (n  106, fasting glucose  126 mg/dl or OGTT
2 h glucose  200 mg/dl). We selected 281 subjects with NGT or IFG only
to minimize the effect of glucose metabolism on RBP4 level. Of these 281
subjects, 217 elderly persons whose height and weight were available
were finally selected (126 NGT and 91 IFG). Of the 217 subjects selected,
177 had normal thyroid function and 40 had SCH, as determined by a
thyroid function test. For the thyroid function test, serum TSH and free
T4 (fT4) concentrations were measured using an immunoradiometric
assay (Abbott, North Chicago, IL). Euthyroidism (Eu) was defined as a
normal level of TSH (0.4–4.1 U/liter) and fT4 (0.7–1.8 ng/dl) in the
absence of thyroid medication. SCH was defined as a TSH concentration
greater than 4.1 U/liter and a normal fT4 concentration. The Institu-
tional Review Board of the Seoul National University Bundang Hospital
approved the study protocol, and written informed consent was obtained
from all subjects.
Questionnaires and anthropometric measurements
During the initial visit, all subjects completed a standardized ques-
tionnaire designed to evaluate their medical history. The questionnaire
included questions about the history of diabetes mellitus, hypertension,
and thyroid dysfunction. All participants attended a standardized clin-
ical interview and underwent physical examination by three clinicians
who were experts in geriatric research. All of the assessments were per-
formed at the Seoul National University Bundang Hospital.
The respondents’ height and weight were measured using an auto-
matic height-weight scale while they wore light clothing. BMI was then
calculated as the ratio between weight and height squared (kilograms per
square meter). Blood pressure was measured twice on one occasion using
a standard mercury sphygmomanometer after 10 min rest while the sub-
ject was in the sitting position. Waist circumference (WC) was measured
at the narrowest point between the lower border of the rib cage and the
iliac crest. Hip circumference (HC) was measured at the level of the
symphysis pubis and the greatest gluteal protuberance. The waist to hip
ratio (WHR) was then calculated by dividing WC by HC.
Measurement of body fat
Percentage body fat and lean body mass were measured using a tet-
rapolar bioelectrical impedance analyzer (Inbody 3.0; Biospace, Seoul,
Korea). Bioelectrical impedance measures two parameters, fat and lean
tissue, using empirically derived formulas, which have been validated
and yield estimates that correlate with estimates obtained using under-
water weighing (28). Abdominal adipose tissue (visceral fat area and sc
fat area; expressed as square centimeters) were quantified using single
computed tomography scans (Somatom Sensation 16; Siemens, Erlan-
gen, Germany). A 5-mm computed tomography slice scan was acquired
at the umbilical level to measure total abdominal and visceral fat area,
and adipose tissue attenuation was then determined by measuring the
mean value for all pixels within the range of 190 to 30 Hounsfield
units.
Measurement of levels of glucose and insulin and lipid
profiles
Plasma glucose concentration was measured using the glucose oxi-
dase method and a YSI 2300 STAT glucose analyzer (Yellow Spring
Instrument Co., Yellow Springs, OH). Plasma insulin concentrations
were measured using a RIA (Linco Research, Chesterfield, MO). The
interassay coefficient of variation was 4%. This assay did not cross-react
with human proinsulin (0.2%). The degree of insulin resistance was
then estimated using the homeostasis model assessment method as de-
scribed by Matthews et al. (29). The homeostasis model assessment for
insulin resistance (HOMA-IR) was computed using the formula: fasting
plasma glucose concentration (millimoles per liter)  fasting serum in-
sulin level (milliunits per liter)/22.5. Total cholesterol, triglycerides (TG),
and high-density lipoprotein (HDL)-cholesterol concentrations were
measured enzymatically using an autoanalyzer (Hitachi 747; Hitachi,
Ltd., Tokyo, Japan). The level of low-density lipoprotein-cholesterol was
estimated using the following formula (30): total cholesterol level 
HDL-cholesterol level  (TG level/5).
Measurement of plasma RBP4 and adiponectin levels
Plasma RBP4 levels were measured using an ELISA (AdipoGen, Inc.,
College of Life Science and Biotechnology, Korea University, Seoul, Ko-
rea) as described in our previous study (31). The ELISA system had an
intraassay coefficient of variation of 4–8% and an interassay coefficient
of variation of 5–10% (31). Adiponectin levels were measured using an
ELISA kit according to the manufacturer’s instructions (AdipoGen).
Statistical analysis
All continuous variables that had a normal distribution are expressed
as the mean  SD. The baseline clinical characteristics of the study sub-
jects were compared using a t test or 2 test and binary logistic regression
analysis as appropriate. Mean RBP4 levels according to the age group
were compared using one-way ANOVA. Bivariate and partial correla-
tion analyses were used to determine the correlation between levels of
RBP4 and TSH. All statistical analyses were performed using SPSS soft-
ware (SPSS Inc., Chicago, IL). P  0.05 was considered statistically
significant.
Results
Clinical and metabolic characteristics of subjects
There were no differences between subjects with Eu and those
with SCH in age, sex, blood pressure, WC, HC, WHR, level of
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fasting plasma glucose, 2-h postload glucose, and hemoglobin
A1c (HbA1c), indices of insulin resistance (fasting insulin level,
HOMA-IR), or lipid profiles (Table 1). BMI, visceral fat area, sc
fat area (SFA), and percentage body fat did not differ between the
Eu and SCH groups. We also classed subjects into a group com-
prising individuals of normal weight (BMI  23 kg/m2) and a
group comprising overweight individuals (BMI  23 kg/m2) on
the basis of the World Health Organization expert consultation
for Asian populations (32). Among the 217 individuals, 111 (Eu:
SCH  86:25) were assigned to the normal weight group and 106
(Eu: SCH  91:15) were assigned to the overweight group. Age,
sex, anthropometric measurements, fasting insulin level, and
HOMA-IR did not differ between the Eu and SCH groups, re-
gardless of the degree of obesity (data not shown). However, TG
level was greater for the SCH group than for the Eu group within
the normal weight group (132.8  63.3 vs. 104.3  60.8 mg/dl,
respectively; P  0.015). Lipid profiles other than TG did not
differ between the Eu and SCH groups.
Correlation of RBP4 concentration with metabolic and
biochemical characteristics
RBP4 level was greater for the SCH group than the Eu group
(Table 1) and was greater for SCH than Eu when individuals in
both the normal weight (51.0  27.7 vs. 77.8  52.4 kg, P 
0.001) and overweight groups (54.2  20.4 vs. 67.5  20.8 kg,
P  0.022) were considered. In addition, RBP4 level was posi-
tively correlated with TSH level in combined Eu and SCH group
and remained significant after adjustment for age, sex, and BMI
(r  0.241, P  0.001, Fig. 1), SFA (r  0.273, P  0.001) or
visceral fat area (VFA) (r  0.263 P  0.002). RBP4 level was
also correlated with adiponectin level (r  0.286, P  0.000)
and systolic blood pressure (SBP) (r  0.209, P  0.002) after
adjustment for age and sex. However, RBP4 level was not cor-
related with BMI, percentage body fat, SFA, or VFA (Fig. 2).
Fasting insulin and HOMA-IR were not correlated with
RBP4 level (data not shown). Although SBP was significantly
correlated with RBP4 level, diastolic blood pressure was not.
There was also no correlation between RBP4 level and obesity
parameters (percentage body fat, VFA, SFA, total fat area, WC,
HC). Furthermore, lipid profiles were not correlated with RBP4
level (data not shown).
TABLE 1. Anthropometric and metabolic characteristics of elderly individuals with Eu or SCH
Eu (n  177) SCH (n  40) P Adjusted Pa
Age (yr) 77.2  8.9 78.6  10.0 0.389
Sex (male:female) 89:88 17:23 0.388
SBP (mm Hg) 129.9  16.3 135.4  21.1 0.127 0.086
Diastolic blood pressure (mm Hg) 82.0  10.2 84.0  12.3 0.344 0.249
BMI (kg/m2) 22.7  3.7 22.4  2.7 0.604 0.792
WC (cm) 85.4  9.0 84.9  10.0 0.757 0.735
WHR 0.93  0.09 0.92  0.09 0.631 0.552
VFA (cm2) 100.8  61.0 95.1  50.7 0.676 0.886
SCA (cm2) 141.5  72.6 153.1  76.6 0.490 0.584
Total fat area (cm2) 242.3  120.4 248.2  116.8 0.830 0.808
Body fat (%) 26.6  7.8 26.7  6.7 0.944 0.614
LBM (kg) 37.9  8.1 37.6  7.6 0.829 0.285
Fasting plasma glucose (mg/dl) 98.2  10.6 95.2  10.6 0.107 0.161
HbA1c (%) 5.65  0.37 5.62  0.35 0.558 0.556
Fasting insulin (U/ml) 4.38  2.58 4.39  2.99 0.840 0.825
HOMA-IR 1.08  0.74 1.05  0.78 0.828 0.599
Total cholesterol (mg/dl) 200.4  37.1 201.7  34.6 0.842 0.914
TG (mg/dl) 123.5  80.5 140.2  77.6 0.124 0.116
HDL-cholesterol (mg/dl) 62.2  16.4 57.3  14.7 0.085 0.098
LDL-cholesterol (mg/dl) 114.7  32.0 117.1  31.0 0.667 0.806
TSH (U/ml) 2.29  0.93 7.67  5.93 0.000 0.953
FT4 (ng/dl) 1.23  0.28 1.17  0.28 0.247 0.342
Adiponectin (g/ml) 11.1  7.2 10.8  7.2 0.768 0.498
RBP4 (g/ml) 52.7  24.2 74.0  47.0 0.000 0.000
a P adjusted for age, sex, and BMI.Values are mean  standard deviation.
LDL, Low-density lipoprotein.
FIG. 1. Plasma RBP4 level was positively correlated with TSH level in
elderly individuals with Eu and SCH after adjustment for age, sex, and
BMI. Pearson correlation coefficient: r  0.241, P  0.001.
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Correlation between age and RBP4 level
Because we enrolled only people over 65 yr of age, we inves-
tigated the association between age and RBP4 level. RBP4 level
did not differ between the age groups (P  0.20), which included
a very old group (over 85 yr), or correlate with age (r  0.025,
P  0.715).
Correlation between adiponectin level and metabolic
and biochemical variables
Although the level of adiponectin was not correlated with
TSH level (r  0.109, P  0.109), age, level of HbA1c, TG, and
HDL-cholesterol, VFA, SFA, WC, HC, lean body mass (LBM),
BMI, fasting insulin level, and HOMA-IR were all significantly
correlated with adiponectin level. However, only HDL-choles-
terol level (r  0.349, P  0.001), VFA (r  0.332, P  0.001),
and TFA (r  0.272, P  0.002) were significantly associated
with adiponectin after the data were adjusted for age, sex, and
BMI.
Discussion
This study indicated that subjects with SCH had significantly
greater plasma RBP4 levels than those with normal thyroid func-
tion and that TSH level was correlated with RBP4 level in elderly
individuals with normal glucose tolerance irrespective of the de-
gree of obesity or the amount of body fat. It has been reported
that RBP4 level is affected by glucose intolerance, obesity, adi-
posity, and age. Of these factors, glucose intolerance has con-
sistently been associated with RBP4 levels (4–10). Therefore, to
exclude the effects of glucose intoler-
ance on RBP4, we analyzed data only
from elderly subjects who had NGT or
IFG only. Plasma RBP4 level was sig-
nificantly correlated with TSH level, re-
gardless of the level of fasting glucose,
HbA1c, fasting insulin, or HOMA-IR,
even though glucose tolerance was
normal.
Although obesity is considered to be
associated with overt hypothyroidism
(33), few studies have been conducted
on SCH. A recent study showed no re-
lationship between SCH and morbid
obesity (mean BMI of subjects was over
52.52 kg/m2) (34). Although the prev-
alence of SCH is greater in obese indi-
viduals, TSH level has only been asso-
ciated with insulin resistance and not
with BMI, fat mass, or LBM (34, 35).
This suggests that obesity or body fat
per se could not explain the metabolic
abnormalities observed in individuals
with SCH. In our study, no significant
correlation was observed between TSH
level and BMI or fat percentage. When
we classed our subjects into two groups
using a BMI cutoff value of 23 kg/m2, plasma RBP4 level was
significantly and positively correlated with TSH level in both the
overweight and normal weight groups. Thus, altered adipocy-
tokine metabolism could be related to metabolic disorders in
SCH.
Several previous studies have shown that RBP4 concentra-
tions are elevated in obese patients (12, 36, 37). However, in our
study plasma RBP4 level did not correlate with BMI or the
amount of visceral fat amount measured using computed to-
mography. Gavi et al. (7) also reported no correlation between
RBP4 level and BMI. Their study included 46 nonobese elderly
individuals aged 60–83 yr who did not have diabetes. Taken
together, factors other than BMI or fat mass may affect circu-
lating RBP4 levels, even though RBP4 is produced by adipocytes.
TG level was significantly greater in the SCH group than the
Eu group within the normal weight group; however, this was not
the case within the overweight group. Although an association
between lipid profile and BMI has been established, TG level is
associated with BMI in men but not women (8, 38). In our study,
the normal-weight group included more male subjects than did
the overweight group, which may explain why we observed a
positive correlation between TG level and BMI only in the nor-
mal-weight group. Some reports have shown that RBP4 affects
fatty acid metabolism (8, 39), but we did not detect a significant
correlation between TG and RBP4 levels in our study.
This study was conducted on individuals aged 65 yr and
older. In this group, RBP4 level was not affected by age, even in
the very old age group (85 yr). Although several studies have
been conducted to elucidate the relationship of RBP4 with age (3,
5–8, 36), only two have demonstrated a positive correlation with
FIG. 2. Plasma RBP4 level was not correlated with BMI (A), fat percentage (B), VFA (C), or SFA (D).
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age (7, 8). It is possible that the level of RBP4 in our elderly
subjects was greater than that of young adults. However, within
the elderly group, an association between RBP4 level and age was
not evident.
We found that plasma adiponectin level was negatively cor-
related with plasma RBP4 level in elderly subjects with euthy-
roidism or SCH. It is well known that adiponectin has a coun-
terregulatory role to that of RBP4. Although several studies have
evaluated the correlation between adiponectin and RBP4 (12) or
other metabolic parameters (13, 40, 41), the mechanism by
which these adipocytokines interact is unclear. Additionally, the
role of adiponectin in hypothyroidism is controversial. Some
authors have reported that adiponectin levels in patients with
hypothyroidism were similar to those in patients with euthyroid-
ism and that adiponectin levels did not change significantly dur-
ing L-thyroxine treatment (42). Others reported a significant as-
sociation between adiponectin and TSH level but did not adjust
their results for other confounding factors (43). Although adi-
ponectin level was negatively correlated with RBP4 level in our
study, further study is required on the mechanism by which the
reciprocal effects of those adipocytokines are exerted.
In summary, plasma RBP4 levels were positively correlated
with TSH levels, regardless of indices of obesity in elderly indi-
viduals with NGT and IFG only. Plasma RBP4 elevation was the
only difference between the Eu and SCH groups. However, the
mechanism by which RBP4 levels are increased in subjects with
SCH remains unknown, and it is unclear whether increased
RBP4 levels are a cause or a result of SCH. Despite these uncer-
tainties, it is possible that elevated RBP4 levels may be associated
with increased cardiometabolic risk in SCH as well as insulin
resistance, obesity, and type 2 diabetes.
Acknowledgments
We thank Man Ick Cho, Ki Choon Moon, and Hye Sook Kim for their
technical assistance.
Address all correspondence and requests for reprints to: Hak C. Jang,
M.D., Ph.D., Department of Internal Medicine, Bundang Hospital, Seoul
National University College of Medicine, 300 Gumi-Dong, Bundang-
Ku, Seongnam-Si, Gyeonggi-Do 463-707, South Korea. E-mail:
janghak@snu.ac.kr.
This work was supported by Korea Science and Engineering Foun-
dation grants funded by the Ministry of Science and Technology
(M10642140004-06N4214-00410) and a grant from the Seoul Re-
search and Business Development Program, Republic of Korea (10526).
Disclosure Summary: The authors have nothing to declare.
References
1. Tamori Y, Sakaue H, Kasuga M 2006 RBP4, an unexpected adipokine. Nat
Med 12:30–31; discussion 31
2. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani
K, Quadro L, Kahn BB 2005 Serum retinol binding protein 4 contributes to
insulin resistance in obesity and type 2 diabetes. Nature 436:356–362
3. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR,
Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB 2006 Retinol-binding
protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl
J Med 354:2552–2563
4. Wolf G 2007 Serum retinol-binding protein: a link between obesity, insulin
resistance, and type 2 diabetes. Nutr Rev 65:251–256
5. Weiping L, Qingfeng C, Shikun M, Xiurong L, Hua Q, Xiaoshu B, Suhua Z,
Qifu L 2006 Elevated serum RBP4 is associated with insulin resistance in
women with polycystic ovary syndrome. Endocrine 30:283–288
6. Broch M, Vendrell J, Ricart W, Richart C, Fernandez-Real JM 2007 Circu-
lating retinol-binding protein-4, insulin sensitivity, insulin secretion, and in-
sulin disposition index in obese and nonobese subjects. Diabetes Care 30:
1802–1806
7. Gavi S, Stuart LM, Kelly P, Melendez MM, Mynarcik DC, Gelato MC, Mc-
Nurlan MA 2007 Retinol-binding protein 4 is associated with insulin resis-
tance and body fat distribution in nonobese subjects without type 2 diabetes.
J Clin Endocrinol Metab 92:1886–1890
8. Lee DC, Lee JW, Im JA 2007 Association of serum retinol binding protein 4 and
insulin resistance in apparently healthy adolescents. Metabolism 56:327–331
9. Craig RL, Chu WS, Elbein SC 2007 Retinol binding protein 4 as a candidate
gene for type 2 diabetes and prediabetic intermediate traits. Mol Genet Metab
90:338–344
10. Polonsky KS 2006 Retinol-binding protein 4, insulin resistance, and type 2
diabetes. N Engl J Med 354:2596–2598
11. Janke J, Engeli S, Boschmann M, Adams F, Bohnke J, Luft FC, Sharma AM,
Jordan J 2006 Retinol-binding protein 4 in human obesity. Diabetes 55:2805–
2810
12. Jia W, Wu H, Bao Y, Wang C, Lu J, Zhu J, Xiang K 2007 Association of serum
retinol binding protein 4 and visceral adiposity in Chinese subjects with and
without type 2 diabetes. J Clin Endocrinol Metab 92:3224–3229
13. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, Fritsche
A, Haring HU 2007 High circulating retinol-binding protein 4 is associated
with elevated liver fat but not with total, subcutaneous, visceral, or intramyo-
cellular fat in humans. Diabetes Care 30:1173–1178
14. Raila J, Henze A, Spranger J, Mohlig M, Pfeiffer AF, Schweigert FJ 2007
Microalbuminuria is a major determinant of elevated plasma retinol-binding
protein 4 in type 2 diabetic patients. Kidney Int 72:505–511
15. Shin MJ, Kang SM, Jang Y, Lee JH, Oh J, Chung JH, Chung N 2007 Serum
retinol binding protein 4 levels are associated with serum adiponectin levels in
non-diabetic, non-obese subjects with hypercholesterolemia. Clin Chim Acta
378:227–229
16. Singh S, Duggal J, Molnar J, Maldonado F, Barsano CP, Arora R 2008 Impact
of subclinical thyroid disorders on coronary heart disease, cardiovascular and
all-cause mortality: a meta-analysis. Int J Cardiol 125(1):41–48
17. Monzani F, Dardano A, Caraccio N 2006 Does treating subclinical hypothy-
roidism improve markers of cardiovascular risk? Treat Endocrinol 5:65–81
18. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy
RP, Ladenson PW 2006 Thyroid status, cardiovascular risk, and mortality in
older adults. JAMA 295:1033–1041
19. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA 2001 Prediction
of all-cause and cardiovascular mortality in elderly people from one low serum
thyrotropin result: a 10-year cohort study. Lancet 358:861–865
20. Rodondi N, Newman AB, Vittinghoff E, de Rekeneire N, Satterfield S, Harris
TB, Bauer DC 2005 Subclinical hypothyroidism and the risk of heart failure,
other cardiovascular events, and death. Arch Intern Med 165:2460–2466
21. Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P,
Michelangeli V 2005 Subclinical thyroid dysfunction as a risk factor for car-
diovascular disease. Archives of Internal Medicine 165:2467–2472
22. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC 2000
Subclinical hypothyroidism is an independent risk factor for atherosclerosis
and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern
Med 132:270–278
23. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F,
Grimley Evans J, Rodgers H, Tunbridge F, Young ET 1996 The development
of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year
follow-up study of an English community. Thyroid 6:155–160
24. Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P,
Michelangeli V 2006 Subclinical thyroid dysfunction and blood pressure: a
community-based study. Clin Endocrinol (Oxf) 65:486–491
25. Luboshitzky R, Aviv A, Herer P, Lavie L 2002 Risk factors for cardiovascular
disease in women with subclinical hypothyroidism. Thyroid 12:421–425
26. Kahaly GJ 2000 Cardiovascular and atherogenic aspects of subclinical hypo-
thyroidism. Thyroid 10:665–679
27. American Diabetes Association 2007 Diagnosis and classification of diabetes
mellitus. Diabetes Care 30(Suppl 1):S42–S47
28. Pacini G, Bergman RN 1986 MINMOD: a computer program to calculate
insulin sensitivity and pancreatic responsivity from the frequently sampled
intravenous glucose tolerance test. Comput Methods Programs Biomed 23:
113–122
J Clin Endocrinol Metab, June 2008, 93(6):2313–2318 jcem.endojournals.org 2317
 at Seoul Natl Univ Central Library Periodicals Rm on December 23, 2009 jcem.endojournals.orgDownloaded from 
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC
1985 Homeostasis model assessment: insulin resistance and -cell function
from fasting plasma glucose and insulin concentrations in man. Diabetologia
28:412–419
30. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentra-
tion of low-density lipoprotein cholesterol in plasma, without use of the pre-
parative ultracentrifuge. Clin Chem 18:499–502
31. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS 2006
Plasma retinol-binding protein-4 concentrations are elevated in human sub-
jects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 29:
2457–2461
32. WHO expert consultation 2004 Appropriate body-mass index for Asian pop-
ulations and its implications for policy and intervention strategies. Lancet
363:157–163
33. Knudsen N, Laurberg P, Rasmussen LB, Bulow I, Perrild H, Ovesen L, Jor-
gensen T 2005 Small differences in thyroid function may be important for body
mass index and the occurrence of obesity in the population. J Clin Endocrinol
Metab 90:4019–4024
34. Michalaki MA, Vagenakis AG, Leonardou AS, Argentou MN, Habeos IG,
Makri MG, Psyrogiannis AI, Kalfarentzos FE, Kyriazopoulou VE 2006 Thy-
roid function in humans with morbid obesity. Thyroid 16:73–78
35. Tagliaferri M, Berselli ME, Calo G, Minocci A, Savia G, Petroni ML, Viberti
GC, Liuzzi A 2001 Subclinical hypothyroidism in obese patients: relation to
resting energy expenditure, serum leptin, body composition, and lipid profile.
Obes Res 9:196–201
36. Von Eynatten M, Lepper PM, Liu D, Lang K, Baumann M, Nawroth PP,
Bierhaus A, Dugi KA, Heemann U, Allolio B, Humpert PM 2007 Retinol-
binding protein 4 is associated with components of the metabolic syndrome,
but not with insulin resistance, in men with type 2 diabetes or coronary artery
disease. Diabetologia 50:1930–1937
37. Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M, Ludvik
B 2007 Serum retinol-binding protein 4 is reduced after weight loss in morbidly
obese subjects. J Clin Endocrinol Metab 92:1168–1171
38. Hu D, Hannah J, Gray RS, Jablonski KA, Henderson JA, Robbins DC, Lee ET,
Welty TK, Howard BV 2000 Effects of obesity and body fat distribution on
lipids and lipoproteins in nondiabetic American Indians: The Strong Heart
Study. Obes Res 8:411–421
39. Erikstrup C, Mortensen OH, Pedersen BK 2006 Retinol-binding protein 4
and insulin resistance. N Engl J Med 355:1393–1394; author reply 1394 –
1395
40. Altinova AE, Toruner FB, Akturk M, Bukan N, Cakir N, Ayvaz G, Arslan M
2006 Adiponectin levels and cardiovascular risk factors in hypothyroidism and
hyperthyroidism. Clin Endocrinol (Oxf) 65:530–535
41. Saito T, Kawano T, Saito T, Ikoma A, Namai K, Tamemoto H, Kawakami M,
Ishikawa SE 2005 Elevation of serum adiponectin levels in Basedow disease.
Metabolism 54:1461–1466
42. Nagasaki T, Inaba M, Hiura Y, Tahara H, Kumeda Y, Shirakawa K, Onoda
N, Ishikawa T, Ishimura E, Nishizawa Y 2005 Plasma levels of adiponectin
and soluble thrombomodulin in hypothyroid patients with normal thyroid
function following levothyroxine replacement therapy. Biomed Pharmacother
59:571–577
43. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F 2005
Relationship of thyroid function with body mass index, leptin, insulin sensi-
tivity and adiponectin in euthyroid obese women. Clin Endocrinol (Oxf) 62:
487–491
2318 Choi et al. RBP4 and TSH Levels in Elderly Subjects J Clin Endocrinol Metab, June 2008, 93(6):2313–2318
 at Seoul Natl Univ Central Library Periodicals Rm on December 23, 2009 jcem.endojournals.orgDownloaded from 
